Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
- Alice T. Shaw
- , Dong Wan Kim
- , Kazuhiko Nakagawa
- , Takashi Seto
- , Lucio Crinó
- , Myung Ju Ahn
- , Tommaso De Pas
- , Benjamin Besse
- , Benjamin J. Solomon
- , Fiona Blackhall
- , Yi Long Wu
- , Michael Thomas
- , Kenneth J. O'Byrne
- , Denis Moro-Sibilot
- , D. Ross Camidge
- , Tony Mok
- , Vera Hirsh
- , Gregory J. Riely
- , Shrividya Iyer
- , Vanessa Tassell
- Massachusetts General Hospital
- Seoul National University
- Kindai University
- National Hospital Organization Kyushu Cancer Center
- University Hospital of Perugia
- Sungkyunkwan University
- IRCCS Istituto Europeo di Oncologia - Milano
- Gustave Roussy
- Peter Maccallum Cancer Centre
- The Christie NHS Foundation Trust
- Guangdong Academy of Medical Sciences
- Heidelberg University
- St James's Hospital
- CHU de Grenoble
- University of Colorado Anschutz Medical Campus
- Chinese University of Hong Kong
- McGill University
- Memorial Sloan-Kettering Cancer Center
- Pfizer Oncology
- Pfizer
- Dana-Farber Cancer Institute
Research output: Contribution to journal › Article › peer-review
3234
Link opens in a new tab
Scopus
citations